6/10/2023

Janusmed kön och genus

Janusmed kön och genus – Zofran

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Ondansetron

Ondansetron

Klass: A

Visa all info

Skriv ut

Kontakta oss

Produkter

Visa alla produkter

Ondansetron, Ondansetron 2care4, Ondansetron Abacus Med......

Ondansetron, Ondansetron 2care4, Ondansetron Abacus Medicine, Ondansetron Accord, Ondansetron Alternova, Ondansetron Aristo, Ondansetron Aurobindo, Ondansetron B. Braun, Ondansetron Bluefish, Ondansetron Copyfarm, Ondansetron EQL Pharma, Ondansetron Ebb, Ondansetron Fresenius Kabi, Ondansetron Hameln, Ondansetron Hexal, Ondansetron Kalceks, Ondansetron Mylan, Ondansetron Nycomed, Ondansetron Orifarm, Ondansetron STADA, Ondansetron Sandoz, Ondansetron Teva, Ondansetron Vian, Setofilm, Zofran, Zofran Syrup, Zofran munlöslig, Zofron munlöslig, Zotrix
ATC-koder

A04AA01

A04AA01
Substanser

Visa alla substanser

ondansetron, ondansetronhydroklorid, ondansetronhydrokl......

ondansetron, ondansetronhydroklorid, ondansetronhydrokloriddihydrat
Sammanfattning

Kvinnor har långsammare utsöndring och högre biotillgänglighet och AUC efter dosering av engångsdos ondansetron. Kvinnor har mer postoperativt och cytostatikaassocierat illamående än män. Liksom med många andra antiemetika får fler män än kvinnor god effekt av ondansetronbehandling. Ondansetron, i synnerhet givet intravenöst i höga doser, är associerat med QT-förlängning på EKG och därmed risk för allvarlig rytmrubbning av typen Torsades de Pointes kammartakykardi. Könsskillnad har inte påvisats för just ondansetron men en känd riskfaktor för att utveckla Torsades de Pointes är kvinnligt kön.

Kvinnor har långsammare utsöndring och högre biotillgänglighet och AUC efter dosering av engångsdos ondansetron. Kvinnor har mer postoperativt och cytostatikaassocierat illamående än män. Liksom med många andra antiemetika får fler män än kvinnor god effekt av ondansetronbehandling. Ondansetron, i synnerhet givet intravenöst i höga doser, är associerat med QT-förlängning på EKG och därmed risk för allvarlig rytmrubbning av typen Torsades de Pointes kammartakykardi. Könsskillnad har inte påvisats för just ondansetron men en känd riskfaktor för att utveckla Torsades de Pointes är kvinnligt kön.
Background

Pharmacokinetics and dosing
In a pharmacokinetic study of healthy volunteers with normal body weight (17 men, 17 women) divided in three age groups; 21-38 years; 61-74 years; and 75-82 years of age, AUC and Cmax values were higher in women than in men after a single oral dose of ondansetron. In women, clearance was found to be lower, oral bioavailability higher due to reduced first-pass uptake of parent drug, and apparent volume of distribution smaller than in men [1]. A cross over study between oral and rectal ondansetron (8 men, 8 women) found similar results with higher AUC and lower clearance in women for both administration forms [2]. Despite the pharmacokinetic differences of ondansetron, the clinical studies have shown effect with similar doses in men and women and no sex differentiation in dosing has been suggested by the manufacturer [3].

Effects
In an open prospective multicenter study of the effect on ondansetron on cisplatin-induced emesis and nausea (16 men, 76 women), 50% of the women had delayed emesis compared to 19% of the men. Treatment failure on worst day was......

Visa hela bakgrundstexten

# Pharmacokinetics and dosing In a pharmacokinetic study of healthy volunteers with normal body weight (17 men, 17 women) divided in three age groups; 21-38 years; 61-74 years; and 75-82 years of age, AUC and Cmax values were higher in women than in men after a single oral dose of ondansetron. In women, clearance was found to be lower, oral bioavailability higher due to reduced first-pass uptake of parent drug, and apparent volume of distribution smaller than in men [1]. A cross over study between oral and rectal ondansetron (8 men, 8 women) found similar results with higher AUC and lower clearance in women for both administration forms [2]. Despite the pharmacokinetic differences of ondansetron, the clinical studies have shown effect with similar doses in men and women and no sex differentiation in dosing has been suggested by the manufacturer [3]. # Effects In an open prospective multicenter study of the effect on ondansetron on cisplatin-induced emesis and nausea (16 men, 76 women), 50% of the women had delayed emesis compared to 19% of the men. Treatment failure on worst day was 30% in women and 0% in men [4]. Similar results were found in another randomized study comparing the antiemetic effect after cisplatine induced nausea of ondansetron with metoclopramide+lorazepam (53 men, 68 women). Treatment success was found in 95% of men and 65% of women [5]. In a cross-over study of chemotherapy induced emesis (270 men, 130 women), women had less chance of complete recovery from emesis [6]. # Adverse effects Several studies have shown ondansetron to prolong the electric repolarization (QT-interval) in the heart, increasing the risk of ventrical arrhythmias [7-9]. In an observational study (17 men, 25 women) on QT-prolongation after ondansetron treatment of post-operative nausea, 9 men and 9 women had ondansetron-induced prolonged QTc-interval [7]. With a few exceptions all ondansetron induced Torsades de pointes have been associated with IV-administration of high doses [8-9]. A warning for 32 mg ondansetron IV has been issued by the FDA [9]. Among the known risk factors of drug induced ventrical arrhythmias are female sex, hypokalemia, bradycardia, and base line QT-prolongation [10]. # Reproductive health issues Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
Försäljning på recept

Visa hela försäljning på recept

Fler kvinnor än män hämtade ut läkemedel innehållande ondansetron (ATC-kod A04AA01) på recept i Sverige år 2015, totalt 14 874 kvinnor och 7 735 män. Det motsvarar 3,1 respektive 1,6 personer per tusen invånare. Andelen som hämtat ut läkemedel var högst i åldersgruppen 70-79 år hos båda könen. I genomsnitt var läkemedel innehållande ondansetron 2,4 gånger vanligare hos kvinnor [11].
Referenser

Visa referenser

  1. Pritchard JF, Bryson JC, Kernodle AE, Benedetti TL, Powell JR. Age and gender effects on ondansetron pharmacokinetics: evaluation of healthy aged volunteers. Clin Pharmacol Ther. 1992;51:51-5.

  2. Jann MW, ZumBrunnen TL, Tenjarla SN, Ward ES, Weidler DJ. Relative bioavailability of ondansetron 8-mg oral tablets versus two extemporaneous 16-mg suppositories: formulation and gender differences. Pharmacotherapy. 1998;18:288-94.

  3. Zofran (ondansetron). Summary of Product Characteristics. Medical Products Agency; 2016.

  4. du Bois A, Meerpohl HG, Vach W, Kommoss FG, Fenzl E, Pfleiderer A. Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetron. Eur J Cancer. 1992;28:450-7.

  5. De Mulder PH, Seynaeve C, Vermorken JB, van Liessum PA, Mols-Jevdevic S, Allman EL et al. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting A multicenter, randomized, double-blind, crossover study. Ann Intern Med. 1990;113:834-40.

  6. Liaw CC, Chang HK, Liau CT, Huang JS, Lin YC, Chen JS. Reduced maintenance of complete protection from emesis for women during chemotherapy cycles. Am J Clin Oncol. 2003;26:12-5.

  7. Charbit B, Albaladejo P, Funck-Brentano C, Legrand M, Samain E, Marty J. Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetron. Anesthesiology. 2005;102:1094-100.

  8. Freedman SB, Uleryk E, Rumantir M, Finkelstein Y. Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketing analysis. Ann Emerg Med. 2014;64:19-25e6.

  9. Food and Drug Administration. FDA drug safety communication: abnormal heart rhythms may be associated with use of Zofran (ondansetron). Food and Drug Administration [www]. [cited 2015-01-14].

  10. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350:1013-22.

  11. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-04-05.]

  1. Pritchard JF, Bryson JC, Kernodle AE, Benedetti TL, Powell JR. Age and gender effects on ondansetron pharmacokinetics: evaluation of healthy aged volunteers. Clin Pharmacol Ther. 1992;51:51-5.
  2. Jann MW, ZumBrunnen TL, Tenjarla SN, Ward ES, Weidler DJ. Relative bioavailability of ondansetron 8-mg oral tablets versus two extemporaneous 16-mg suppositories: formulation and gender differences. Pharmacotherapy. 1998;18:288-94.
  3. Zofran (ondansetron). Summary of Product Characteristics. Medical Products Agency; 2016.
  4. du Bois A, Meerpohl HG, Vach W, Kommoss FG, Fenzl E, Pfleiderer A. Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetron. Eur J Cancer. 1992;28:450-7.
  5. De Mulder PH, Seynaeve C, Vermorken JB, van Liessum PA, Mols-Jevdevic S, Allman EL et al. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting A multicenter, randomized, double-blind, crossover study. Ann Intern Med. 1990;113:834-40.
  6. Liaw CC, Chang HK, Liau CT, Huang JS, Lin YC, Chen JS. Reduced maintenance of complete protection from emesis for women during chemotherapy cycles. Am J Clin Oncol. 2003;26:12-5.
  7. Charbit B, Albaladejo P, Funck-Brentano C, Legrand M, Samain E, Marty J. Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetron. Anesthesiology. 2005;102:1094-100.
  8. Freedman SB, Uleryk E, Rumantir M, Finkelstein Y. Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketing analysis. Ann Emerg Med. 2014;64:19-25e6.
  9. Food and Drug Administration. FDA drug safety communication: abnormal heart rhythms may be associated with use of Zofran (ondansetron). Food and Drug Administration [www]. [cited 2015-01-14].
  10. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350:1013-22.
  11. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-04-05.]
Uppdaterat

Litteratursökningsdatum 1/13/2015

Litteratursökningsdatum 1/13/2015